Editorial increased many folds over the recent years with availability of rituximab biosimilars,
which has drastically cut down the marketing cost of the drug.[12] Though concerns have …

Pemphigus poses a therapeutic challenge and rituximab is increasingly used in its
treatment. Long‐term data regarding efficacy and safety of rituximab in pemphigus is limited …

Background: Pemphigus is a group of potentially fatal autoimmune mucocutaneous
blistering diseases. Rituximab (RTX) is a chimeric anti-CD20 (anti-cluster of differentiate 20) …

Background: Rituximab is being increasingly used for the treatment of pemphigus. Data
derived from single-center studies following a uniform treatment protocol are limited. Effect of …

Aim The aim of our study was to assess the effectiveness of one such drug, Rituximab, a
biological, in treating pemphigus vulgaris and to identify common adverse events. Materials …

Objective Rituximab, a chimeric monoclonal antibody that targets the CD-20 molecule on B-
cells' surface, has led to significant advances in the treatment of autoimmune pemphigus in …

Background: Pemphigus is a group of auto-immune blistering disorders, characterised
clinically by mucocutaneous blisters and erosions and histopathologically by intra-epidermal …

Background: Rituximab, a monoclonal anti-CD20 antibody, has been used with encouraging
results in pemphigus. We describe herein refractory cases of pemphigus vulgaris (n= 23) …

Sir, Systemic glucocorticoids with or without adjuvant immunosuppressants has been the
mainstay for the treatment of chronic blistering disorders such as pemphigus since decades; …

Dear Editor, Rituximab (RTX), an anti-CD20þ agent, has been approved for the treatment of
moderate-to-severe Pemphigus vulgaris (1, 2). Based on the updated S2K guidelines on the …